Biphenyl Compounds

"Biphenyl Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings.

Descriptor ID	D001713
MeSH Number(s)	D02.455.426.559.389.185
Concept/Terms	Biphenyl Compounds Biphenyl Compounds Compounds, Biphenyl

Below are MeSH descriptors whose meaning is more general than "Biphenyl Compounds".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Biphenyl Compounds [D02.455.426.559.389.185]

Below are MeSH descriptors whose meaning is related to "Biphenyl Compounds".

Below are MeSH descriptors whose meaning is more specific than "Biphenyl Compounds".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biphenyl Compounds" by people in this website by year, and whether "Biphenyl Compounds" was a major or minor topic of these publications.

Bar chart showing 23 publications over 16 distinct years, with a maximum of 2 publications in 2002 and 2008 and 2009 and 2015 and 2019 and 2020 and 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	1	1	2
2004	1	0	1
2005	0	1	1
2008	1	1	2
2009	0	2	2
2010	0	1	1
2012	0	1	1
2013	1	0	1
2014	1	0	1
2015	2	0	2
2018	0	1	1
2019	1	1	2
2020	0	2	2
2021	0	1	1
2022	1	1	2

Below are the most recent publications written about "Biphenyl Compounds" by people in Profiles.

Gabot A, Lavitas P, Bacon R, Pomfret TC, Taylor M, Coelho A, Greenwood BC, Alper CJ, Clements KM, Lenz K. Cost-benefit analysis of sacubitril/valsartan in a Medicaid population. Am J Manag Care. 2022 07; 28(7):349-352.

View in: PubMed
Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):17-25.

View in: PubMed
Kim YS, Brar S, D'Albo N, Dey A, Shah S, Ganatra S, Dani SS. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovasc Drugs Ther. 2022 10; 36(5):915-924.

View in: PubMed
Sani MA, Tavassoli M, Hamishehkar H, McClements DJ. Carbohydrate-based films containing pH-sensitive red barberry anthocyanins: Application as biodegradable smart food packaging materials. Carbohydr Polym. 2021 Mar 01; 255:117488.

View in: PubMed
Dani SS, Ganatra S, Vaduganathan M. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. Int J Cardiol. 2021 01 15; 323:188-191.

View in: PubMed
Maslov MY, Foianini S, Mayer D, Orlov MV, Lovich MA. Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats. J Card Fail. 2019 Nov; 25(11):921-931.

View in: PubMed
Ma L, Pak ML, Ou J, Yu J, St Louis P, Shan Y, Hutchinson L, Li S, Brehm MA, Zhu LJ, Green MR. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proc Natl Acad Sci U S A. 2019 05 21; 116(21):10482-10487.

View in: PubMed
Maslov MY, Foianini S, Mayer D, Orlov MV, Lovich MA. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure. Am J Physiol Heart Circ Physiol. 2019 02 01; 316(2):H289-H297.

View in: PubMed
Chen X, Zhang J, Han C, Dai H, Kong X, Xu L, Xia Q, Zhang M, Zhang J. A sexual dimorphism influences bicyclol-induced hepatic heat shock factor 1 activation and hepatoprotection. Mol Pharmacol. 2015 Jul; 88(1):38-47.

View in: PubMed
Ellsworth P, Fantasia J. Solabegron: a potential future addition to the ?-3 adrenoceptor agonist armamentarium for the management of overactive bladder. Expert Opin Investig Drugs. 2015 Mar; 24(3):413-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals